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1  | INTRODUC TION
Chronic kidney disease (CKD) is a major public health concern due to 
its increased prevalence, high morbidity and mortality associated, high 
costs, poorer quality of life and reduced life expectancy.1 CKD is as-
sociated with an increased cardiovascular (CV) risk, and CV disease 
accounts for nearly half of all deaths.2 The increased incidence of CV 
disease (CVD) in CKD cannot be explained by the high prevalence of 
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Abstract
Endothelial dysfunction is an earlier contributor to the development of atherosclero-
sis in chronic kidney disease (CKD), in which the role of epigenetic triggers cannot be 
ruled out. Endothelial protective strategies, such as defibrotide (DF), may be useful 
in this scenario. We evaluated changes induced by CKD on endothelial cell proteome 
and explored the effect of DF and the mechanisms involved. Human umbilical cord 
vein endothelial cells were exposed to sera from healthy donors (n = 20) and patients 
with end-stage renal disease on haemodialysis (n = 20). Differential protein expres-
sion was investigated by using a proteomic approach, Western blot and immuno-
fluorescence. HDAC1 and HDAC2 overexpression was detected. Increased HDAC1 
expression occurred at both cytoplasm and nucleus. These effects were dose-de-
pendently inhibited by DF. Both the HDACs inhibitor trichostatin A and DF prevented 
the up-regulation of the endothelial dysfunction markers induced by the uraemic 
milieu: intercellular adhesion molecule-1, surface Toll-like receptor-4, von Willebrand 
Factor and reactive oxygen species. Moreover, DF down-regulated HDACs expres-
sion through the PI3/AKT signalling pathway. HDACs appear as key modulators of 
the CKD-induced endothelial dysfunction as specific blockade by trichostatin A or by 
DF prevents endothelial dysfunction responses to the CKD insult. Moreover, DF ex-
erts its endothelial protective effect by inhibiting HDAC up-regulation likely through 
PI3K/AKT.
K E Y W O R D S
chronic kidney disease, defibrotide, endothelial dysfunction, HDAC, HDAC1, HDAC2, 
inflammation, oxidative stress
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traditional risk factors in this setting, and classical CV risk scores, such 
as the Framingham risk score, underestimate the CV risk in this popu-
lation.3 Further, the results of pharmacological interventions that have 
proven a cardio-protective benefit in the general population or other 
high risk populations (eg in diabetes or in patients with established 
cardiovascular disease), such as statins or inhibitors of the renin-an-
giotensin system, have failed to show a benefit in patients with end-
stage renal disease.4-7 Because of that, new or uraemia-related CV risk 
factors have been postulated to play a role in the CV risk of these 
patients.8 Thus, there is a need for the search of new therapies able to 
reduce the high CV risk and the associated mortality in this population.
There is wide evidence indicating that endothelial dysfunction 
is an initial stage for the development of atherosclerosis, and in vivo 
and in vitro studies have demonstrated that endothelial dysfunction 
is present in CKD.9 In previous in vitro studies, endothelial dysfunc-
tion induced by the CKD milieu has been characterized. Exposure 
of endothelial cells (ECs) to sera from CKD patients results in mor-
phological alterations, enhanced thrombogenicity of the extracel-
lular matrix and changes towards a pro-inflammatory phenotype, 
with increased expression of adhesion receptors and activation of 
signalling pathways, such as nuclear factor-kappa B (NFkB),10 or the 
innate immunity Toll-like receptor 4 (TLR4) and the NALP3 inflam-
masome.11 Moreover, the endothelial response to the CKD insult is 
also characterized by an enhanced oxidative stress and changes in 
the expression of related proteins.12-15
Our previous in vitro results suggest that the CKD setting induces 
activation of specific genes in the endothelium that promotes a proo-
xidant, pro-inflammatory, prothrombotic and proproliferative state. In 
this regard, HDACs enzymes are important epigenetic factors that reg-
ulate pro-inflammatory gene expression, in ECs and in other tissues, 
and also deacetylate non-histone proteins that regulate inflamma-
tory signalling.16 Therefore, they appear to be promising therapeutic 
targets for the treatment of atherosclerosis and other cardiovascular 
diseases.17,18 Furthermore, HDAC activity is linked to a number of car-
dio-renal pathologies, including heart failure,19 hypertension,20 and 
diabetes or diabetic kidney disease.21,22 Thus, the dysfunctional en-
dothelium and its epigenetic regulation arise as an attractive target 
for interventions designed to reduce the risk and burden of CVD in 
CKD patients.23,24 Defibrotide (Defitelio®) (DF) is a drug composed 
by a complex single-stranded oligodeoxyribonucleotides derived from 
porcine intestinal mucosal DNA that has demonstrated profibrinolytic, 
antithrombotic-thrombolytic, antiischaemic, antishock, antiatheroscle-
rotic, antirejection and anti-angiogenic effects.25 The endothelial pro-
tective activity of this drug has been demonstrated in different clinical 
settings.26-28 This drug interacts specifically with the membrane of ECs 
where it displays its anti-inflammatory and anti-oxidant effects.29
In the present study, we applied a translational approach12 to iden-
tify proteins differentially expressed in an endothelium exposed to the 
CKD milieu and the effect of DF. Functional assays were performed to 
confirm the role of the most physiologically relevant identified proteins 
and their implication in the development of endothelial dysfunction. 
Moreover, we aimed at identifying the mechanisms involved in the pro-
tective effect exerted by DF in this setting.
2  | METHODS
2.1 | Patients and sample collection
Sera from patients with end-stage renal disease on maintenance 
haemodialysis (HD, n = 20) were included. Patient characteristics are 
detailed in Table 1. In order to exclude causes other than uraemia in 
endothelial dysfunction, patients with diabetes, dyslipidaemia and/
or previous CVD and/or current smokers were excluded. All CKD 
patients were dialysed with biocompatible membranes, ultrapure 
water, for ≥4 hours, three times a week with a Kt/V ≥ 1.3. None of the 
patients were dialysed through an HD catheter as a vascular access. 
Blood samples were collected before the 2nd or 3rd HD session of 
the week. Sex and age-matched healthy donors (n = 20), with no pre-
vious history of CVD, and preserved renal function (eGFR > 90 mL/
min/1.73 m2, CKD-EPI formula) were enrolled as controls (Table 1). 
Serum samples from CKD patients and from healthy donors were 
obtained by centrifugation of non-anticoagulated blood (3000 g, 
15 minutes) and stored at −80°C until used. Pools of serum were 






Age, years, mean ± SD 48.3 ± 9.3 55.4 ± 15.7
Female/male 12/8 9/11
Estimated filtration rate CKD-
EPI (mL/min/1.73 m2)
>90 0
Mean time on dialysis, 
months ± SD
 23 ± 5.7
Dialysis adequacy, Kt/V, mean, 
±SD
 2.3 ± 0.4
Serum albumin (g/L), 
mean ± SD
44 ± 4 39 ± 6
CRP (mg/dL), mean ± SD 0.2 ± 0.1 0.4 ± 0.2
Haemoglobin (g/L), mean ± SD 12.6 ± 1.6 11.3 ± 0.4
Leucocytes (109/L), mean ± SD 7.4 ± 1.6 6.8 ± 1.2
Causes of CKD n (%)
Glomerulonephritis  4 (20%)
Polycystic kidney disease  3 (15%)
Interstitial nephropathy  4 (20%)
Obstructive kidney disease  2 (10%)
Nephrosclerosis  3 (15%)
Unknown  4 (20%)
Hypertension n (%) 0 14 (70%)
Use of statins n (%) 0 8 (40%)
Use of vitamin D n (%) 0 18 (90%)
Use of erythropoiesis stimu-
lating agents n (%)
0 17 (85%)
Use of inhibitors of the renin-
angiotensin system n (%)
0 6 (30%)
Abbreviation: CRP, C-Reactive protein.
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prepared containing serum samples from different healthy donors 
or HD patients, which were used as reagent for the different experi-
ments performed.
2.2 | Endothelial cell cultures
ECs were isolated from human umbilical cord veins.30 Cells were 
maintained and subcultured at 37°C in a 5% CO2 humidified in-
cubator in EGM-2 Endothelial Cell Growth Medium-2 BulletKit 
(Lonza, Cultek SLU). Culture medium was replaced every 48 hours. 
To perform the experiments, ECs were used between the 2nd 
and 3rd passage. To study the CKD-induced endothelial dam-
age, we used an established in vitro model of uraemic endothelial 
dysfunction.11,13-15,24 This model consists of exposing endothelial 
cells to Medium 199 (Gibco BRL, Life Technologies) supplemented 
with 100 U/mL penicillin, 100 g/mL streptomycin (Gibco BRL, Life 
Technologies) and 20% of pooled sera from patients (n = 20) or from 
matched healthy donors (n = 20), for different periods depending on 
the endothelial damage marker to be evaluated.
2.3 | Differential proteomic analysis
ECs were isolated from human umbilical cord veins (n = 6) and cul-
tured as previously described. After reaching confluence during the 
first passage, cells were mixed, seeded in 75-cm2 flasks and exposed 
to media containing 20% of pooled sera of controls (n = 20 distributed 
in 6 different pools) or CKD patients (n = 20 distributed in 6 different 
pools) with or without DF (100 μg/mL, a dose selected from our previ-
ous studies)27,29 during 24 hours. Then ECs were washed, trypsinized, 
counted, pelleted and stored at –80°C until proteomic analysis.
Each sample was then solubilized in Laemmli lysis buffer 
(60 mmol/L Tris HCl, pH 6.8, 2.2% (w/v) SDS, 5% (v/v) glycerol, 
0.1 mol/L DTT), incubated for 3 minutes at 99°C, sonicated and 
centrifuged for 15 minutes. Protein concentration was determined 
using the Quick Start Bradford Protein Assay (Bio-Rad) following 
the manufacturer's recommendation.31 Then, 100 µg of proteins 
was separated by using SDS-PAGE 12% acrylamide gel. The gel 
was fixed with 30% ethanol and 10% acetic acid and precondi-
tioned with sodium thiosulphate, before silver nitrate staining 
treatment with the modified Blum et al32 silver staining proto-
col. Gels were cut into 3 mm slices prior to trypsin digestion and 
peptide extraction.33 Peptides were separated by means of nano 
liquid chromatography using a Proxeon EASY-nLC (Thermo Fisher 
Scientific) with a flow rate of 300 nL/min, a C18 trap column 
(5 µm, 120 Å, 100 µm inner diameter 2 cm in length), an EASY 
C18 analytical column (3 µm, 120 Å, 75 µm inner diameter 10 cm 
in length). The following linear gradient, using solvent B (97% ace-
tonitrile, 0.1% formic acid) and solvent A (3% acetonitrile, 0.1% 
formic acid), was employed: 5%-40% buffer B (90 minutes); 40%-
100% buffer B (5 minutes); 100% buffer B (15 minutes) finally. MS/
MS analysis was performed using an LTQ Orbitrap Velos (Thermo 
Fisher Scientific) coupled to a nanoelectrospray ion source 
(Thermo Fisher Scientific). MS/MS data acquisition was completed 
using Xcalibur 2.1 (Thermo Fisher Scientific).34
Data were processed using Proteome Discoverer 1.2 (Thermo 
Fisher Scientific). For database searching, processed data were 
submitted to the in-house Homo sapiens UniProtKB/Swiss-Prot 
database (released June 2011; 20 211 protein entries) using 
SEQUEST, version 28.0 (Thermo Fisher Scientific). The follow-
ing search parameters were used: two maximum missed cleav-
ages for trypsin; carbamidomethylation as a fixed modification; 
methionine oxidation as a variable modification; 20 pp peptide 
mass tolerance; and 0.8 Da fragment ion tolerance. Criteria used 
to accept identification included a false discovery rate (FDR) of 
0.05, and five minimum spectra (and at least one unique pep-
tide) matched per protein. Proteins identified were classified ac-
cording to biological function(s) using the information available 
at the UniProt Knowledge base (UniProtKB/Swiss-Prot) website 
(http://www.unipr ot.org) and checked according to previous de-
scriptions found in PubMed (http://www.ncbi.nlm.nih.gov/pubme 
d/; National Center for Biotechnology Information, US National 
Library of Medicine, National Institutes of Health, Bethesda, MD). 
Spectral counts were normalized using the average of the sum of 
raw counts across all samples. Differentially expressed proteins 
were identified using stringent selection criteria: fold change ≥3 
for up-regulated proteins, detected in all samples and a mean nor-
malized count in positive samples of ≥2.
2.4 | Confirmation of proteins by Western blot and 
immunofluorescence studies
From the differentially up-regulated proteins found comparing the an-
alysed settings, both HDAC1 and HDAC2 were selected to be deeply 
studied. First, protein lysates from ECs exposed to the same condi-
tions studied in the proteomic assay were analysed by Western blot 
(WB, n = 4) and immunofluorescence (IF, n = 6) with specific primary 
antibodies (Abcam) to confirm the proteomic results.
For WB analysis, ECs were exposed to media containing 20% of 
pooled sera of controls (4 different pools) or CKD patients (4 different 
pools) with or without DF (100 μg/mL, a dose selected from our previ-
ous studies)27,29 during 24 hours. Then, ECs were lysed with Laemmli's 
buffer, sonicated to shear DNA and reduce viscosity (15 seconds), and 
heated to 90°C (5 minutes). Protein concentration in the supernatants 
was determined using Coomassie Plus (Pierce). Samples were resolved 
by 8% SDS-PAGE, proteins transferred to nitrocellulose membranes 
and probed with specific antibodies against HDAC1, HDAC2 (Abcam) 
and B-actin (Cell Signaling). Membranes were incubated with a per-
oxidase-conjugated anti-rabbit IgG and developed by chemilumines-
cence.29 Densitometric assay of protein bands was performed using 
Fiji (ImageJ, National Institutes of Health), and all values were normal-
ized with their respective B-actin bands.
For IF analysis, ECs were exposed to the same conditions pre-
viously described, fixed with 4% paraformaldehyde in 0.15 mol/L 
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PBS, pH 7.4 (4°C, 10 minutes), blocked with 1% BSA, permeabilized 
with triton X-100 (Sigma) and incubated with a primary antibody 
against HDAC1 and a secondary antibody anti-rabbit IgG conju-
gated with Alexa 488 (Molecular probes). Nuclei were stained with 
DAPI (Sigma). Samples were evaluated by a fluorescence micros-
copy (Leica DM4000B), images were captured through a video cam-
era (Leica DFC310FX), and the percentage of the area positive for 
staining was calculated by computerized establishing a threshold 
through morphometric analysis (Fiji, ImageJ, National Institutes of 
Health). Moreover, with the aim of analysing the location of HDAC1, 
a colour threshold tool defining blue colour was used to differenti-
ate nuclei (blue) and cytoplasm (not blue). Then, HDAC1 expression 
was differentially quantified in these two compartments. Moreover, 
to evaluate the specificity of HDAC1 inhibition by DF, a dose-de-
pendent study (0, 50 and 100 µg/mL) was performed by using an 
IF assay.
2.5 | Roles of HDAC1 and HDAC2 in endothelial 
damage induced by CKD sera
To evaluate the role of HDAC1 and HDAC2 in uraemic endothe-
lial dysfunction, a pan-HDAC inhibitor trichostatin A (TSA) (Sigma 
Aldrich) and DF were used as HDAC inhibitors. ECs on 6-well mi-
croplates were pretreated (24 hours) with TSA (50 nmol/L) or DF 
(100 µg/mL) and exposed to media containing 20% of pooled sera 
from the uraemic patients or healthy donors, as previously described 
for the differential proteomic analysis. Cells were then fixed and 
labelled for intercellular adhesion molecule-1 (ICAM-1) (Millipore, 
Merck), Toll-like receptor 4 (TLR4) (Abcam) and von Willebrand 
Factor (vWF) (DAKO) using IF, as previously described. Reactive oxy-
gen species (ROS) production was explored by using CM-H2DCFDA. 
This compound can passively diffuse into cells being oxidized by ROS 
to the highly fluorescent dichlorofluorescein. ROS production was 
monitored by fluorescence microscopy. All samples were evaluated 
by microscopy (Leica DM4000B), and images were captured through 
a videocamera (Leica DFC310FX). Fluorescence micrographs were 
analysed using ImageJ (version 1.43m; NIH, http://rsb.info.nih.gov/
nih-image/ manua l/tech.html#). Cultured cells were selected from 
the background with the threshold tool, and the fluorescence inten-
sity was measured.
2.6 | Activation of PI 3-kinase/AKT pathway as 
inducer of HDAC1 and HDAC2 expression and 
inhibitory effect of defibrotide
740 Y-P (Tocris Bioscience, Bio-Techne R&D Systems, S.LU), a cell-
permeable PI 3-kinase/AKT activator, was used as reagent to inves-
tigate the interaction between DF and HDAC1 and HDAC2. 740 Y-P 
was added (20 μmol/L, 5 hours) to ECs cultures in the presence or 
absence of DF and HDAC1 and HDAC2 expression was evaluated 
through IF (n = 6) and WB (n = 4).
2.7 | Study approval
Written informed consent was obtained from all participants, and 
the study was approved by the Ethical Committee of the Hospital 
Clinic (HCB/2014/0302) and carried out according to the principles 
of World Medical Association Declaration of Helsinki.
2.8 | Statistics
Results are expressed as mean ± standard error of the mean (SEM) 
and correspond to the % of labelled area/% of nuclei area for IF as-
says when analysing total HDAC1 expression, in % of labelled area 
when analysing HDAC1 expression in nuclei or cytoplasm, and in fold 
increase vs control for the values obtained from densitometric analysis 
of the protein bands normalized with their respective B-actin bands 
for WB. N corresponds to different experiments performed with dif-
ferent pools (from healthy donors or CKD patients) for each value ana-
lysed. Statistical analysis was performed using SPSS statistical package 
17.0.0 (SPSS Inc, Chicago, IL) with raw data using t test. Results were 
considered statistically significant when P < .05.
3  | RESULTS
3.1 | Endothelial dysfunction in CKD is 
characterized by an increase in HDAC1 and HDAC2, 
among other proteins
To study the proteomic changes involved in endothelial uraemic dys-
function and the potential protective role of DF in this setting, a pro-
teomic approach was performed on ECs exposed to sera of healthy 
controls or CKD patients in the absence and presence of DF. After 
normalization, 11 proteins were differentially expressed comparing 
the analysed settings (Table 2). Proteins related to inflammation, such 
as protein arginine N-methyltransferase 5 or histone arginine meth-
yltransferase; proteins involved in epigenetic regulation and proteins 
related to cell motility; proliferation and survival (HDAC1, HDAC2, 
ATP-dependent DNA helicase Q1, TRIO and F-acting-binding pro-
tein), among others were overexpressed in the uraemic setting. 
Results suggested that DF could re-establish the proper expression of 
proteins that were found overexpressed in the ECs exposed to CKD 
conditions.
3.2 | DF prevents the overexpression of HDAC1 and 
HDAC2 induced by CKD sera, as well as increased 
HDAC1 in both nucleic and cytoplasmic locations
WB and IF techniques were applied to confirm HDAC1 and HDAC2 
overexpression in ECs exposed to CKD sera and the effect of 
DF. WB results confirmed that CKD induced an overexpression 
of HDAC1 (1.9 ± 0.3 fold vs Control, n = 4, P < .05) and HDAC2 
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(1.5 ± 0.1 fold vs Control, n = 4, P < .05) that was normalized in the 
presence of DF (1.1 ± 0.2 for HDAC1, and 0.9 ± 0.2 for HDAC2, 
n = 4 and P < .05 vs CKD for all experiments) (Panel A, Figure 1). 
Similarly, an increase in HDAC1 was detected by IF in ECs exposed 
to CKD from 3 ± 0.3% of labelled area/% nuclei area in controls to 
4.7 ± 0.2% of labelled area/% nuclei area in CKD (n = 6, P < .01). 
The effect of uraemic sera on endothelial HDAC1 expression 
was prevented by DF (2.6 ± 0.1% of labelled area/% nuclei area, 
n = 6, P < .01 vs CKD) (Micrographs and left scatterplot, Panel B, 
Figure 1). Specifically at the nucleus, CKD sera induced a signifi-
cant increase in HDAC1 (77.5 ± 2.9% vs 50.3 ± 2.4% of nuclei la-
belled area in control samples, n = 6, P < .01), which was prevented 
by DF (41.8 ± 5.2% of nuclei labelled area, n = 6, P < .01 vs CKD). In 
addition, the effect of DF was also notable in the cytoplasmic loca-
tion in ECs exposed to CKD, as the overexpression of the protein 
in ECs exposed to uraemic sera vs controls was reduced to almost 
75% of cytoplasmic labelled area (Micrographs and right scatter-
plot, Panel B, Figure 1).
3.3 | The inhibitory effect of DF on CKD-induced 
HDAC1 overexpression is dose-dependent
Immunofluorescence assays were performed with different DF doses to 
test the specificity of the reduction of HDAC1 expression previously de-
tected. In ECs exposed to CKD sera, HDAC1 total expression increased 
to 4.7 ± 0.2% of labelled area/% nuclei area compared to control, and was 
dose-dependently inhibited in the presence of 50 μg/mL (4.2 ± 0.3% of 
labelled area/% nuclei area, n = 6,) and 100 μg/mL (3.8 ± 0.1% of labelled 
area/% nuclei area, n = 6, P < .05 vs CKD) of DF (Figure 2).
3.4 | CKD-induced endothelial dysfunction 
is mediated through HDAC1 and HDAC2 
overexpression
ICAM-1 and TLR4 expression on cell surfaces and vWF con-
tent were higher in ECs exposed to the CKD patients’ sera when 
TA B L E  2   Overexpressed proteins in endothelial cells exposed to CKD sera
Swiss-Prot 






Ligase, activation of long-chain 
fatty acids for both synthesis of 
cellular lipids, and degradation via 
beta-oxidation
Fatty acid metabolism, lipid 
metabolism
O14744 Protein arginine 
N-methyltransferase 5
PRMT5 Golgi apparatus, nu-
cleus, and cytoplasm
Chromatin regulator methyl-






CEBPZ Nucleus Activator Transcription regulation
Q9UJW0 Dynactin subunit 4 DCTN4 Cytoskeleton, cell cor-
tex, and sarcomere
Protein N-terminus binding Endoplasmic reticulum to Golgi 
vesicle-mediated transport 
and nuclear migration
Q9BY44 Eukaryotic translation 
initiation factor 2A
EIF2A Cytosol, extracellular 
region, and secreted
Initiation factor Protein biosynthesis and trans-
lation regulation
Q92556 Engulfment and cell 
motility protein 1
ELMO1 Plasma membrane SH3 domain binding Actin cytoskeleton organiza-
tion, apoptotic process, and 
vascular endothelial growth 
factor receptor signalling 
pathway
Q13451 Peptidyl-prolyl cis-trans 
isomerase FKBP5
FKBP5 Nucleus and 
cytoplasm
Heat shock protein binding Chaperone-mediated protein 
folding
Q96I24 Far upstream element-
binding protein 3
FUBP3 Nucleus DNA-binding transcription acti-
vator activity, RNA polymerase 
II-specific, and RNA binding




GBP4 Golgi apparatus and 
nucleus
GTPase activity Cellular response to 
interferon-gamma
Q13547 Histone deacetylase 1 HDAC1 Nucleus Chromatin regulator, Hydrolase, 
and repressor
Biological rhythms and 
Transcription regulation
Q92769 Histone deacetylase 2 HDAC2 Nucleus and 
cytoplasm
Chromatin regulator, hydrolase, 
and repressor
Biological rhythms and tran-
scription regulation
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compared to control sera (1.5 ± 0.2%, 0.8 ± 0.1%, and 7.5 ± 0.9% vs 
0.6 ± 0.1%, 0.4 ± 0.1%, and 3.9 ± 0.2%, respectively, n = 6, P < .05). 
Exposure of ECs to CKD sera in the presence or absence of TSA 
was performed to assess if HDAC1 and HDAC2 overexpression me-
diated the increases in markers of endothelial damage induced by 
CKD. Our results point out that inhibition of HDACs overexpression 
reduced the increase in the markers of endothelial damage evalu-
ated. In the presence of TSA, ICAM-1 expression was reduced from 
1.5 ± 0.2% to 0.9 ± 0.1%, TLR4 from 0.8 ± 0.1% to 0.4 ± 0.1%, vWF 
from 7.5 ± 0.9% to 3.6 ± 0.4% and ROS production from 4.1 ± 2.1 of 
mean fluorescence intensity to 21.8 ± 2.0% (P < .05 for all values) 
(Figure 3). Furthermore, DF was also capable to inhibit the expres-
sion of ICAM-1, TLR4 and vWF content on cells exposed to uraemic 
sera in a significant manner, decreasing their expression to control 
levels (0.4 ± 0.1%, 0.4 ± 0.1% and 4.1 ± 0.2%, respectively, n = 6, 
P < .05 vs CKD for ICAM and P < .05 vs CKD for TLR4 and vWF) 
(Figure 3). DF also exhibited a remarkably and significant inhibitory 
effect on ROS generation in response to the uraemic sera, reduc-
ing its production to control levels (18.1 ± 1.3 of mean fluorescence 
intensity, n = 6, P < .05 vs CKD) (Figure 3).
3.5 | Effect of DF on HDAC1 and HDAC2 
is potentially mediated through PI3K/AKT 
pathway inhibition
ECs were exposed to P740-Y-P, a cell-permeable phosphopeptide 
activator of the PI3K/AKT pathway in the presence or absence of 
DF (100 μg/mL). Then, HDAC1 expression was assessed by WB and 
IF, and HDAC2 by WB (Figure 4).
WB results revealed that the expression of HDAC1 and HDAC2 was 
increased in ECs incubated with P740-Y-P (5 hours) (fold of 1.9 ± 0.1 
and 1.4 ± 0.2, respectively vs control, n = 4, P < .05) and that these 
increases were prevented by DF (0.9 ± 0.1 and 1.1 ± 0.2 fold vs control, 
F I G U R E  1   Defibrotide prevents 
HDAC1 increased expression induced 
by CKD sera at both nucleic and 
cytoplasmatic locations. A, Immunoblot 
images show expression of HDAC1 (left) 
and HDAC2 (right) when endothelial 
cells were exposed to control or CKD 
sera (24 h) in the absence or presence of 
DF (100 µg/mL). B, Micrographs show 
HDAC1 expression (green) in endothelial 
cells exposed to control and CKD sera in 
the absence or presence of defibrotide 
(CKD + DF). Left column shows total 
presence of HDAC1 (green) and nucleic 
(blue) staining. The middle column shows 
HDAC1 expression only in the nuclei 
and the right column shows HDAC1 
expression only in the cytoplasm (40× 
magnification). Left scatterplot (with 
median) represents HDAC1 expression in 
terms of the total percentage of labelled 
area/percentage of nuclei area, and right 
scatterplot represent HDAC1 expression 
in terms of the total percentage of labelled 
area in nuclei or cytoplasm, in endothelial 
cells exposed to healthy sera (Control) and 
sera from CKD patients with or without 
the presence of defibrotide (CKD and 
CKD + DF, respectively) (n = 6, being 
**P < .01 vs control and ##P < .01 vs CKD, 
n = number of independent experiments, 
statistical analysis was performed with 
raw data using t test)
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respectively). Moreover, through an IF assay HDAC1 overexpression 
in the nuclei was confirmed after the incubation of ECs with P740-
Y-P (from 32.6 ± 4.4% of covered area to 44.9 ± 6.4%, n = 6, P < .05). 
Defibrotide was able to prevent this increase (27.6 ± 5.9, n = 6, P < .05).
4  | DISCUSSION
Our present study explored the protein signature of the endothe-
lium exposed to CKD sera in the presence and absence of DF, and 
pointed out to HDACs as key molecules that mediate the endothelial 
response to the CKD milieu. Both TSA and DF prevented the en-
dothelium from developing its pro-inflammatory, prooxidant, pro-
thrombotic and activated innate immunity phenotype induced by 
the CKD sera. Further, PI3K/AKT signalling pathway was identified 
as a putative pathway through which DF modulates HDACs expres-
sion (Figure 5). Thus, the results of the present study highlight the 
relevance of the epigenetic changes associated with endothelial dys-
function in CKD and uncover the potential mechanisms of action by 
which DF exerts its protective effect on ECs in this setting.
The involvement of vascular endothelium in the initiation and the 
progression of atherosclerosis in CKD patients has been progres-
sively recognized. So far, the endothelial phenotype in CKD has been 
extensively characterized, but there is a lack of information regarding 
the mechanisms through which the uraemic milieu exerts an impact 
on the endothelial cell and its epigenome. To approach this knowl-
edge, we applied an established translational methodology12 to look 
for the signature of endothelial dysfunction in CKD and find key fac-
tors that may be susceptible to be regulated by DF. We were able 
to identify two proteins, HDAC1 and HDAC2, involved in epigenetic 
regulation, among other up-regulated proteins. Epigenetics refer to 
chromatin-based mechanisms important in the regulation of gene ex-
pression that do not involve changes in the DNA sequence per se.35,36
Our proteomic results were confirmed by other techniques 
and revealed that the CKD milieu induces overexpression of both 
HDAC1 and 2 and the accumulation of HDAC1 in both the nucleus 
and the cytoplasm of ECs. These two enzymes are widely expressed 
in human tissues, belong to class I HDACs, which are considered the 
‘classical’ HDACs, whose activities could be inhibited by TSA, and 
are involved in cell proliferation and cell survival.37 Although HDAC 
class I (HDAC 1, 2, 3 and 8) is classically described as being expressed 
in the nucleus, these proteins are also found in the cytosol. In this 
sense, several studies have shown that HDAC1 can also be expressed 
in the cytosol in different cell lines,38-40 and although its expression 
is mainly located in the nucleus, its expression is enhanced in the 
cytosol in pathological conditions.41 Further, it has been reported 
that the up-regulation of HDAC1 in ECs deacetylates nitric oxide 
synthase 3 (NOS3), directly resulting in a decrease of endothelial ni-
tric oxide production.42 HDAC overexpression in ECs in response to 
CKD sera is in concordance with previous evidence by other authors 
showing enhanced expression of these proteins in other cardio-renal 
pathologies.19-22 The protective effect of DF in this setting concord 
with its proved beneficial effect in other clinical entities associated 
with endothelial dysfunction.27-29
HDACs positively act on pro-inflammatory candidates, such as 
cytokines (IL-6, IL-12, TNF), chemokines (CCL2, CCL7 and CXCL) 
and other inflammatory mediators (MMP-9 and endothelin-1).43,44 
In this regard, HDACs inhibitors show broad anti-inflammatory ef-
fects through different mechanisms. In our model of uraemic en-
dothelium, both TSA and DF reduced ICAM-1 expression and vWF 
production. Moreover, there are many studies demonstrating the 
important role of HDACs both in innate and adaptive immunity. In 
particular, these enzymes seem to act on the expression of TLR tar-
get genes.45 In this regard, we show in the present study that TLR4 
expression is regulated by HDACs in ECs exposed to a uraemic mi-
lieu. In addition, the inhibition of ROS production by TSA and DF 
demonstrates that HDACs are also involved in the prooxidant endo-
thelial response to CKD.
F I G U R E  2   Defibrotide prevents HDAC1 increased expression 
induced by CKD sera in a dose-dependent manner. Micrographs 
show endothelial cells exposed to CKD sera in absence (up) 
and presence of defibrotide (50 µg/mL and 100 µg/mL). Nuclei 
are labelled with DAPI (blue) (40× magnification). Scatterplot 
(with median) represents quantification of the area positive for 
HDAC1 staining normalized by percentage of nuclei area, by 
immunofluorescence technique (n = 6, being *P < .05 vs control 
and #P < .05 vs CKD, n = number of independent experiments, 
statistical analysis was performed with raw data using t test)
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The pharmacological inhibition of HDACs is a new target for sev-
eral disorders. These drugs have been approved for the treatment 
of some lymphomas, or epilepsy (valproic acid) and several others 
are in clinical trials. Further, these agents have shown its efficacy in 
animal models of inflammatory diseases, attenuating the progres-
sion of renal fibrogenesis in obstructive nephropathy or reducing 
cyst formation in polycystic kidney disease.46 This property has been 
successfully applied to ameliorate endothelial activation and vascular 
F I G U R E  3   ICAM-1, TLR4, vWF and ROS increases in CKD are mediated through HDACs induction. Micrographs show enhanced 
expression of the adhesion receptor ICAM-1 (red), TLR4 (red), the adhesive protein vWF (red) and production of ROS (green) when 
endothelial cells were exposed to CKD patients' sera. The co-incubation of cells with CKD patients sera and TSA (CKD + TSA, middle row) 
or defibrotide (CKD + DF, lower row) induced a decrease in the expression of the markers of endothelial damage analysed. Cell nuclei are 
stained with DAPI (blue) (40× magnification). Scatterplots (with median) correspond to the quantification of the endothelial damage markers 
evaluated. All data correspond to relative expression compared to control levels (n = 6, being *P < .05 vs control and #P < .05 and ##P < .01 
vs CKD, n = number of independent experiments, statistical analysis was performed with raw data using t test)
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pathophysiology in sickle cell anaemia in transgenic mice. In this ex-
perimental animal model, and also in HUVECs,47,48 TSA significantly 
reduced VCAM-1 and tissue factor expression.49 Although many of 
the underlying mechanisms and functions of HDACs in human cells 
are poorly understood and remain unclear, they appear to be promis-
ing targets in the modulation of endothelial dysfunction.
Once we demonstrated that DF is able to reduce HDACs expres-
sion and their downstream effects in the CKD-induced endothelial 
damage, we focused on the search of the signalling pathway po-
tentially used by the drug to modulate these epigenetic regulators. 
There is evidence demonstrating that HDAC expression is regulated 
by the PI3K/AKT pathway.17,50 In addition, our group has previously 
F I G U R E  4   Defibrotide acts as a PI3/
AKT inhibitor to interact with HDACs. 
A, Immunoblot images show expression 
of HDAC1 (left) and HDAC2 (right) when 
endothelial cells were exposed to 740 Y-P 
in absence or presence of DF (100 µg/
mL). B, Micrographs show an increase in 
HDAC1 expression (green) in endothelial 
cells exposed to P740-Y-P (+P740-Y-P) 
and a decrease when DF was added (+740 
Y-P + DF). Scatterplot (with median) 
represents the quantification of HDAC1 
expression in the three situations (Control, 
+740 Y-P, +740 Y-P + DF) in terms of the 
labelled area (n = 6, being *P < .05 vs 
control and #P < .05 vs CKD, n = number 
of independent experiments, statistical 
analysis was performed with raw data 
using t test)
F I G U R E  5   Visual abstract. A single, concise, pictorial and visual summary of the main findings of the present study in which we 
demonstrate that HDACs appear as key modulators of the CKD-induced endothelial dysfunction and that DF prevents endothelial 
dysfunction responses to the CKD insult likely through PI3K/AKT
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demonstrated that DF inhibits the activation of PI3K/AKT.27,51 Both 
facts prompted us to hypothesize that DF was regulating HDACs 
through this pathway. To prove this hypothesis, ECs were exposed 
to a PI3K/AKT inducer to stimulate HDAC expression, and then, the 
effect of DF was explored. Our results indicate that DF could act as 
a PI3K/AKT pathway inhibitor to modulate HDACs expression. One 
of the limitations of our study is that we measured protein levels, 
but not HDACs activity or other HDACs not appearing in our pro-
teomic approach. Another limitation of our study is that we used a 
pan-HDAC inhibitor rather than specific HDAC1 or 2 inhibitor, and 
its effects on other HDACs cannot be ruled out.
In conclusion, CKD is an example of a complex disease in which the 
phenotype arises from a combination of environmental and inheritable 
factors.52 Evidence suggests that the contribution of the uraemic milieu 
may be mediated via modifications of the epigenome. The findings of 
the present study revealed a role for HDACs as key modulators of the 
endothelial phenotype in response to the CKD insult. These enzymes 
seem to mediate, at least in part, the endothelial enhanced oxidative 
stress, the up-regulation of the innate immunity, and the pro-inflamma-
tory and pro-thrombogenic responses. In addition, we provide strong 
evidence showing that DF may confer a protection to the endothelium 
from the uraemic insult acting as a potential HDAC modulator. Finally, 
DF seems to exert its endothelial protective effect by inhibiting HDAC 
up-regulation likely through PI3K/AKT signalling pathway.
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